CRLHealthcare · Diagnostics & ResearchThe 17 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $330 — +1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Quality (59): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.2% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $300 → $340 |
| 30 Sept 2026 | UBS | Reinstates | Buy | $357 |
| 28 Sept 2026 | Jefferies | Maintains | Buy | — |
| 28 Sept 2026 | Jefferies | Maintains | Buy | $305 → $340 |
| 25 Sept 2026 | Baird | Maintains | Outperform | — |
| 25 Sept 2026 | Baird | Maintains | Outperform | $291 → $334 |
| 25 Sept 2026 | Barclays | Maintains | Overweight | — |
| 25 Sept 2026 | Barclays | Maintains | Overweight | $300 → $330 |
| 25 Sept 2026 | Deutsche Bank | Maintains | Buy | $300 → $320 |
| 25 Sept 2026 | Deutsche Bank | Maintains | Buy | — |
| 25 Sept 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Sept 2026 | Evercore ISI Group | Maintains | Outperform | $320 → $330 |
| 25 Sept 2026 | Mizuho | Maintains | Neutral | $264 → $295 |
| 25 Sept 2026 | Mizuho | Maintains | Neutral | — |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | — |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | $282 → $322 |
| 25 Sept 2026 | TD Cowen | Maintains | Buy | $300 → $325 |
| 25 Sept 2026 | TD Cowen | Maintains | Buy | — |
| 11 Sept 2026 | Evercore ISI Group | Maintains | Outperform | $300 → $320 |
| 11 Sept 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CRL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Charles River Laboratories International, Inc. returned +83.4% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 27% of US stocks
Cheaper than 16% of US stocks
Cheaper than 12% of US stocks
Higher than 23% of US stocks
Higher than 34% of US stocks
Higher than 44% of US stocks
Higher than 73% of US stocks
Higher than 23% of US stocks
Higher than 37% of US stocks
Higher than 72% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Charles River Laboratories International, Inc. has a market value of $16.9B and an enterprise value of $19.1B.
Revenue in the twelve months to 30 June 2026: $4.0B. The latest quarter shrank 2.7% year on year.
Net income over the same four quarters: −$236.3M, a −5.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.85.
Free cash flow in the twelve months to 30 June 2026: $370.6M, after $211.5M of capital spending.
Charles River Laboratories International, Inc. spent $324.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 681.3×; forward P/E: 27.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.34%, paying out 0% of earnings.
Charles River Laboratories International, Inc. employs 18,300 people — $219K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Charles River Laboratories International, Inc.’s Q3 2026 earnings call.
Why it matters — The transcript provides CRL watchers with the company’s discussion during its Q3 2026 earnings call.
Charles River reported third-quarter earnings and revenue above estimates, with organic growth and margin expansion contributing to the results. The company also raised its 2026 outlook.
Why it matters — CRL watchers may note the stronger-than-expected quarterly results and the raised 2026 outlook.
Zacks Investment Research says Charles River’s Q3 revenue and EPS provide a view of its performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago figures.
Why it matters — Those comparisons may provide CRL watchers additional context on quarterly performance beyond revenue and EPS.
Charles River Laboratories reported quarterly earnings of $3.09 per share, exceeding the Zacks Consensus Estimate of $2.98. Earnings were $2.43 per share in the year-ago quarter.
Why it matters — The earnings beat and year-over-year increase are relevant to investors tracking CRL’s quarterly results.
Charles River Laboratories announced its third-quarter 2026 results, but the provided excerpt contains no details about the results.
Why it matters — CRL watchers may want to review the company’s quarterly results; no performance information is included in the excerpt.
The 17 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $330, with estimates ranging from $145 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Charles River Laboratories International, Inc., 14 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 90 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Charles River Laboratories International, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +1.2% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 90 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $390 over the next 12 months.
Charles River Laboratories International, Inc. returned +83.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Charles River Laboratories International, Inc. is a life sciences company that provides products and services supporting pharmaceutical and biotechnology research, drug discovery, non-clinical development, and safety assessment.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Charles River Laboratories International, Inc.’s Q3 2026 earnings call.
Charles River Laboratories International, Inc. is a life sciences company that provides products and services supporting pharmaceutical and biotechnology research, drug discovery, non-clinical development, and safety assessment. Its Research Models and Services business supplies purpose-bred rodents and genetically defined research models, along with related services used in laboratory and preclinical studies. Through Discovery and Safety Assessment, the company conducts regulated and non-regulated in vitro, in vivo, and in silico studies, laboratory support, consulting, and program management for potential medicines. Its Manufacturing Solutions activities include microbial testing and biologics-related services that help address quality, contamination control, and development requirements. Charles River Laboratories International, Inc. serves pharmaceutical and biotechnology companies, government agencies, academic institutions, and other research organizations across international life sciences markets. Its integrated role connects early laboratory research with the testing and development processes required to advance medical products toward regulatory review.
CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com
